NOVARTIS NNN

NOVARTIS N

94.03CHFD
+1.30+1.40%
At close at May 30, 21:51 GMT
CHF
No trades
See on Supercharts

NOVN fundamentals

Key facts

Market capitalization‪178.96 B‬CHF
Founded1996
Employees (FY)‪75.88 K‬
CEOVasant Narasimhan
About

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Ownership
‪‪1.90 B‬‬
Free Float shares
‪‪1.69 B‬‬ (89.07%)
Closely held shares
‪‪207.31 M‬‬ (10.93%)
Free Float shares
‪‪1.69 B‬‬ (89.07%)
Closely held shares
‪‪207.31 M‬‬ (10.93%)
Capital structure
Market cap
‪‪178.96 B‬‬
Debt
‪‪27.67 B‬‬
Minority interest
‪‪73.43 M‬‬
Cash & equivalents
‪‪6.37 B‬‬
Enterprise value
‪‪200.33 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪178.96 B‬‬
Price to earning ratio (P/E)
16.35x
Price to sales ratio (P/S)
4.00x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
16.35x
Price to sales ratio (P/S)
4.00x
Valuation ratios
‪0.00‬
‪1.20‬
‪2.40‬
‪3.60‬
‪4.80‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪5.00‬
‪10.00‬
‪15.00‬
‪20.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪20%‬
‪22%‬
‪24%‬
‪26%‬
‪28%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪3.00 B‬‬
‪‪6.00 B‬‬
‪‪9.00 B‬‬
‪‪12.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪3.00 B‬‬
‪‪6.00 B‬‬
‪‪9.00 B‬‬
‪‪12.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪3.00 B‬‬
‪‪6.00 B‬‬
‪‪9.00 B‬‬
‪‪12.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Oncology
Established Brands
Immunology
Cardiovascular, Renal and Metabolic
Neuroscience
By country
Period: 2024
United States
Europe
Asia/Africa/Australasia
China
Germany
Canada and Latin America
France
Switzerland

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪‪3.00 B‬‬
‪‪6.00 B‬‬
‪‪9.00 B‬‬
‪‪12.00 B‬‬
Actual
Estimate
Earnings
Next:Jul 17, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪0.55‬
‪1.10‬
‪1.65‬
‪2.20‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
61.31%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
3.72%
Last payment
3.50
Last ex-date
Mar 11, 2025
Last pay date
Mar 13, 2025
Dividend history
‪3.50%‬
‪3.62%‬
‪3.74%‬
‪3.86%‬
‪3.98%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.90‬
‪1.80‬
‪2.70‬
‪3.60‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪8.00 B‬‬
‪‪16.00 B‬‬
‪‪24.00 B‬‬
‪‪32.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪17.00 B‬‬
‪‪34.00 B‬‬
‪‪51.00 B‬‬
‪‪68.00 B‬‬
Assets
Liabilities